CPC C07K 16/40 (2013.01) [A61K 38/57 (2013.01); A61P 1/04 (2018.01); C12N 9/00 (2013.01); C12N 9/48 (2013.01); C12N 15/115 (2013.01); C12N 15/1137 (2013.01); C12Q 1/37 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/12 (2013.01); C12N 2310/14 (2013.01); C12N 2310/16 (2013.01); G01N 2333/96433 (2013.01); G01N 2500/02 (2013.01); G01N 2500/10 (2013.01); G01N 2800/065 (2013.01)] | 4 Claims |
1. A method of treating Inflammatory Bowel Diseases (IBD), Irritable Bowel Syndrome (IBS) or gluten hypersensitivity in a patient in need thereof, comprising
administering to the patient a therapeutically effective amount of an elastase 2A (ELA2A) inhibitor,
wherein the ELA2A inhibitor is an anti-ELA2A neutralizing antibody, or
an aptamer, or
an inhibitor of ELA2A gene expression selected from a small inhibitory RNA (siRNA) and an antisense oligonucleotide.
|